Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 205, Issue 4, Pages 981-992Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20071854
Keywords
-
Categories
Funding
- NCI NIH HHS [CA006927, P30 CA006927] Funding Source: Medline
- NIAID NIH HHS [U54-AI57168, R01 AI065544, U54 AI057168, AI065544] Funding Source: Medline
Ask authors/readers for more resources
Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of mousepox), encode immune response modifiers (IRMs) that can increase virulence by decreasing the host immune response. We show that one of these IRMs, the type I interferon (IFN) binding protein ( bp) of ECTV, is essential for ECTV virulence and is a natural target of the antibody response. More strikingly, we demonstrate that immunization with recombinant type I IFN bp protects mice from lethal mousepox. Collectively, our experiments have important implications for our understanding of the role of IRMs in OPV virulence and of type I IFNs in OPV infections. Furthermore, our work provides proof of concept that effective antiviral vaccines can be made to prevent disease by targeting virulence factors as an alternative to the traditional approach that attempts to prevent infection by virus neutralization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available